Latest news with #Chalasani
Time of India
09-07-2025
- Business
- Time of India
SIPs hit new high in June as D-Street uncertainty eases
MUMBAI: After a few months of flat growth in inflows by retail investors through SIPs in mutual fund schemes, the northward movement is back. In June, gross inflows through SIPs in MFs - an investment segment within the MF industry that is dominated almost entirely by retail investors - touched a new all-time peak at Rs 27,269 crore. This showed a monthly jump of 2.2%, data released by industry body Amfi for June showed. The month's growth number and the new peak in terms of gross flows came after seven months of stagnation when every month the inflow figure hovered around the Rs 26K mark. The month's figure also showed that the total assets under management (AUM) of the fund industry also scaled a new peak, at Rs 74.8 lakh crore. According to Amfi chief Venkat Chalasani, these growth numbers - in monthly SIP inflows and the total industry AUM - continued to be powered by strong retail participation. "The number of contributing SIP accounts also touched an all-time high of 8.64 crore, underlining the growing trust in mutual funds as a disciplined investment vehicle," he said. Chalasani also pointed out that net inflows into equity funds during June was at Rs 23,587 crore, which was the 52nd consecutive month of positive flows. "While market volatility has made some investors cautious, we're also witnessing a healthy shift towards hybrid and arbitrage funds, a trend that shows maturing investor behaviour and a preference for balanced risk strategies in uncertain times." by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like Dieses Hörgerät kann 2025 alles verändern Gutes Hören Undo June data for the fund industry also showed that SIP AUM for the industry was at Rs 15.3 lakh crore, translating to 20.6% of the total MF industry AUM, up from 20.2% in May. "The continued strength of SIPs underscores disciplined participation from retail investors. The inflows recorded in June may signify a turning point, reflecting enduring structural confidence in Indian equities and a growing risk appetite," Samco MF CEO Viraj Gandhi said. He also said that in June, inflows in small- and mid-cap funds continued to outpace those in large-cap segment. Outside of equity, "gold ETFs saw inflows of nearly Rs 2,000 crore, suggesting investor interest to seek both diversification and also gain from the performance of the metal," said Anand Vardarajan, chief business officer, Tata MF. Stay informed with the latest business news, updates on bank holidays and public holidays . AI Masterclass for Students. Upskill Young Ones Today!– Join Now
Time of India
09-07-2025
- Business
- Time of India
Mutual fund SIP inflows touch record high: June investments hit Rs 27,269 crore, up 2% from May; contributing SIP accounts cross 8.64 crore for first time
Monthly investments through systematic investment plans (SIPs) surged to a new peak of Rs 27,269 crore in June 2025, up 2% from Rs 26,688 crore in May, crossing the Rs 27,000 crore mark for the first time, according to fresh data from AMFI. The SIP assets under management (AUM) rose to Rs 15.30 lakh crore in June, from Rs 14.61 lakh crore the previous month, highlighting the continued momentum in retail participation in mutual funds, according to an ET report. The number of contributing SIP accounts hit an all-time high of 8.64 crore, compared to 8.56 crore in May and 8.38 crore in April, showing consistent investor engagement despite market fluctuations. Meanwhile, new SIP registrations jumped to 61.91 lakh, up from 59.14 lakh in May and 46.01 lakh in April. Retail folios under equity, hybrid and solution-oriented schemes climbed to 19.07 crore in June, up from 18.84 crore a month earlier. The corresponding retail AUM rose to Rs 44.40 lakh crore, against Rs 42.20 lakh crore in May. The broader mutual fund ecosystem also saw growth, with the total number of MF folios expanding to 24.13 crore from 23.83 crore in May and 23.62 crore in April. Overall industry AUM climbed 3% month-on-month to touch Rs 74.14 lakh crore, setting a new record from Rs 71.93 lakh crore in May. AMFI chief executive Venkat Chalasani said 'The mutual fund industry's AUM crossing Rs 74 lakh crore in June marks a significant milestone. This progress is fuelled by strong and sustained retail interest, as seen in the record SIP inflows of Rs 27,269 crore and all-time high 8.64 crore SIP accounts. It reflects growing investor confidence in mutual funds as a disciplined investment route.' Chalasani also noted that equity fund inflows remained strong at Rs 23,587 crore, marking the 52nd straight month of net positive flows. He added that even amid market uncertainties, investors were showing a shift toward hybrid and arbitrage strategies, suggesting a maturing approach to risk. 'Our focus is on building a resilient mutual fund ecosystem, supported by transparent disclosures and continued investor education. We remain committed to deepening retail participation and encouraging savers to stay invested for long-term wealth creation,' Chalasani said, quoted the financial daily. He reaffirmed confidence in India's economic trajectory, urging investors to remain aligned with their financial objectives despite short-term volatility. Stay informed with the latest business news, updates on bank holidays and public holidays . AI Masterclass for Students. Upskill Young Ones Today!– Join Now
Yahoo
10-06-2025
- Health
- Yahoo
Galectin Therapeutics to Host Virtual KOL Event to Discuss Belapectin for Treatment of MASH Cirrhosis and Portal Hypertension
NORCROSS, Ga., June 10, 2025 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin-3 for patients with MASH cirrhosis and portal hypertension, today announced that it will host a virtual key opinion leader (KOL) event on Monday, June 16, 2025 at 12:00 PM ET. To register, click here. The event will focus on the unmet need and current treatment landscape for metabolic dysfunction-associated steatohepatitis (MASH) cirrhosis and portal hypertension. Featured KOLs will include: Naga P. Chalasani, MD, Professor of Gastroenterology and Hepatology, Adjunct Professor of Anatomy, Cell Biology and Physiology, & Director of Terance Kahn Liver Research Program, Indiana University School of Medicine; and Naim Alkhouri, MD, FAASLD, DABOM, Chief Academic Officer, Summit Clinical Research, & Director of the Steatotic Liver Program, North Shore Gastroenterology, Cleveland, OH. The event will highlight results from Galectin's NAVIGATE Phase 3 clinical trial evaluating belapectin for the treatment of MASH cirrhosis and portal. Belapectin is a complex carbohydrate drug that targets galectin-3, a critical protein in the pathogenesis of MASH and fibrosis. With no approved therapies to prevent or treat varices in MASH cirrhosis, belapectin may represent the first potential treatment to address this significant unmet need. A live question and answer session will follow the formal presentations. About Naga P. Chalasani, MD Naga P. Chalasani, MD completed medical school in India before he moved to the US to pursue Internal Medicine residency at Emory University in Atlanta, followed by a fellowship in Gastroenterology and Hepatology at the same institution. He joined IU in 1997 as an Assistant Professor in the Division of Gastroenterology and Hepatology. Dr. Chalasani is currently David W. Crabb Professor of Gastroenterology and Hepatology and Adjunct Professor of Anatomy, Cell Biology & Physiology and as Director of Terance Kahn Liver Research Program at Indiana University School of Medicine. He previously served as the GI Division Chief (2007-2020), Associate Dean for Clinical Research (2017-2020) interim Chair of the Department of Medicine (2020-2021) and Vice President for Academic Affairs at Indiana University Health (2022-2024). He is a highly regarded clinician and ranked as Top Doctor continuously for over 15 years. He has been continuously funded by the National Institutes of Health (NIH) since 1999 and is currently the PI on several U01 and R01 awards from the NIH. Dr. Chalasani is considered an authority in the fields of Non-Alcoholic Fatty Liver Disease (NAFLD) and Drug Induced Liver Injury (DILI), two highly significant public health problems. He is one of the most published and most cited investigators at Indiana University, with Google Scholar H-Index 120 and 75,000 citations (as of Feb 2025). He is an elected member of the American Society of Clinical Investigation (ASCI), the American Association of Physicians (AAP) and the National Academy of Medical Sciences – India (2024). He has mentored over 75 undergraduate and graduate students, medical students, sub-specialty trainees, and junior faculty. Twenty of his mentees are recipients of federal funding (K award, U01, R21, R01, DOD, and VA Merit Review). To honor his contributions and mentorship, Naga P Chalasani Endowed Professor in Gastroenterology and Hepatology has been established at Indiana University School of Medicine in October 2022. About Naim Alkhouri, MD, FAASLD, DABOM Naim Alkhouri, MD, FAASLD, DABOM is the Chief Academic Officer at Summit Clinical Research and the Director of the Steatotic Liver Program at North Shore Gastroenterology in Cleveland, OH. Prior to joining Summit, Dr. Alkhouri served as the Chief Medical Officer and Director of the Steatotic Liver Disease program at Arizona Liver Health in Phoenix, AZ. Dr. Alkhouri is a key opinion leader in the field of MASH therapeutics and an advisor/ consultant to many pharmaceutical and biomarker development companies. He is Principal Investigator on several multicenter global MASH trials and a member of the AASLD MASLD Special Interest Group (MASLD SIG). Dr. Alkhouri has been published in over 260 publications to include publications in the New England Journal of Medicine, Lancet, JAMA, Nature Medicine, Gastroenterology, Hepatology, and Journal of Hepatology. He presents his work at both national and international medical conferences. About Galectin Therapeutics Galectin Therapeutics is dedicated to developing novel therapies to improve the lives of patients with chronic liver disease and cancer. Galectin's lead drug belapectin is a carbohydrate-based drug that inhibits the galectin-3 protein, which is directly involved in multiple inflammatory, fibrotic, and malignant diseases, for which it has Fast Track designation by the U.S. Food and Drug Administration. The lead development program is in metabolic dysfunction-associated steatohepatitis (MASH, formerly known as nonalcoholic steatohepatitis, or NASH) with cirrhosis, the most advanced form of MASH-related fibrosis. Liver cirrhosis is one of the most pressing medical needs and a significant drug development opportunity. Additional development programs are in treatment of combination immunotherapy for advanced head and neck cancers and other malignancies. Advancement of these additional clinical programs is largely dependent on finding a suitable partner. Galectin seeks to leverage extensive scientific and development expertise as well as established relationships with external sources to achieve cost-effective and efficient development. Additional information is available at Forward-Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements relate to future events or future financial performance, and use words such as 'may,' 'estimate,' 'could,' 'expect', 'look forward', 'believe', 'hope' and others. They are based on management's current expectations and are subject to factors and uncertainties that could cause actual results to differ materially from those described in the statements. These statements include those regarding the hope that Galectin's development program for belapectin will lead to the first therapy for the treatment of MASH, formerly known as NASH, with cirrhosis and those regarding the hope that our lead compounds will be successful in cancer immunotherapy and in other therapeutic indications. Factors that could cause actual performance to differ materially from those discussed in the forward-looking statements include, among others, full analysis of the NAVIGATE trial data may not product positive data; Galectin may not be successful in developing effective treatments and/or obtaining the requisite approvals for the use of belapectin or any of its other drugs in development; the Company may not be successful in scaling up manufacturing and meeting requirements related to chemistry, manufacturing and control matters; the Company's current clinical trial and any future clinical studies may not produce positive results in a timely fashion, if at all, and could require larger and longer trials, which would be time consuming and costly; plans regarding development, approval and marketing of any of Galectin's drugs are subject to change at any time based on the changing needs of the Company as determined by management and regulatory agencies; regardless of the results of any of its development programs, Galectin may be unsuccessful in developing partnerships with other companies or raising additional capital that would allow it to further develop and/or fund any studies or trials. Galectin has incurred operating losses since inception, and its ability to successfully develop and market drugs may be impacted by its ability to manage costs and finance continuing operations. For a discussion of additional factors impacting Galectin's business, see the Company's Annual Report on Form 10-K for the year ended December 31, 2024, and subsequent filings with the SEC. You should not place undue reliance on forward-looking statements. Although subsequent events may cause its views to change, management disclaims any obligation to update forward-looking statements. Company Contact:Jack Callicutt, Chief Financial Officer(678) 620-3186ir@ Investor Relations Contact:Kevin Gardnerkgardner@ Galectin Therapeutics and its associated logo is a registered trademark of Galectin Therapeutics Inc. Belapectin is the USAN assigned name for Galectin Therapeutics' galectin-3 inhibitor belapectin.
The Hindu
02-06-2025
- Business
- The Hindu
Implement revised local sourcing norms for wind turbines immediately: Suzlon Group's Chalasani
As India plans to have 500 GW non-fossil energy capacity by 2030, wind energy is expected to contribute a fifth of that target. Yet, with only 4% of its 1.1 TW (Tera Watt) wind potential tapped, the sector's true challenge lies not in potential, but in execution said J.P. Chalasani, CEO, Suzlon Group, one of India's largest renewable energy companies, in an interview. He said policy reform, cybersecurity, and indigenous R&D were crucial for the success of the wind energy sector in the country. 'Revised List of Models and Manufacturers (RLMM) reforms are a start. Implementation can not wait,' he emphasised. The Ministry of New and Renewable Energy (MNRE) recently revised its RLMM guidelines, mandating local sourcing of critical components like blades, gearboxes, generators, and towers. RLMM guidelines must mandate this not just for new models, but for all existing listings as well, he stated. The revised RLMM guidelines were also to strengthen cybersecurity norms. 'It is a strategic shift—but over a year late. The guidelines must now be implemented swiftly and without dilution,' he pointed out. Stating that India's wind manufacturing ecosystem was more than ready, he said, 'We have over 20 GW turbine manufacturing capacity, but only 20% is utilised. Our blade capacity is 28 GW, including 11 GW from independent manufacturers. Generator capacity is 17 GW—yet underutilised.' The new policy, if enforced, could restore local content levels to 75% by 2026 and 85% by 2028, he stated. Emphasizing the danger of cyber threat to the wind turbines and the grid Mr Chalasani said, 'Wind turbines are not just machines—they are grid-connected, data-exchanging systems. A single breach can ripple into a national grid failure,' he warned. 'Cybersecurity is not compliance—its sovereignty,' he mentioned. He urged mandatory certification of all digital and hardware components—especially those of foreign origin—by Indian agencies such as Central Electricity Authority, MeitY, and Standardization Testing and Quality Certification (STQC) Directorate. 'Embedded malware and hardware trojans are real risks. We need deep protocol-level checks,' he said. MNRE's latest draft also mandates that all turbine operations, data centres, and control systems reside within India—a move which is 'non-negotiable for national security,' he said. Recalling the contribution of late Tulsi Tanti, the founder and MD of Suzlon Energy, Mr Chalasani said, 'He was not just a founder, he was the spirit of Indian renewables. The turnaround we have achieved is our tribute to his vision,' he said. Mr Tanti suddenly passed away in October 2022 raising a question mark on Suzlon's future. Under Mr. Chalasani's leadership, Suzlon has become debt-free and cash-rich, with ₹2,000 crore on its balance sheet. The company's latest 3.15 MW turbine model—engineered for Indian terrain and climate—has been a success. Today, Suzlon has an order book of 5.5 GW, over half of it from industrial and commercial consumers (C&I), and nearly 26% from public sector giants like NTPC and SJVN. 'India Inc. wants reliable green power. Being Indian-designed, Indian-operated, with 25-year service support—that is our edge,' he said. Unlike solar, which he called a 'commodity technology,' Mr. Chalasani, an energy sector veteran said, wind turbines are engineering-intensive and site-specific. 'You can not just import a design meant for Europe and tweak it for Rajasthan,' he said Locally designed and tested turbines reduce downtime, minimise grid disruptions, and enhance long-term operational efficiency, he pointed out. On the government's policy support, he said for too long, Indian OEMs had competed on an uneven field against foreign players importing partially built turbines. 'These new guidelines give us, finally, a level playing field,' he emphasized.
Time of India
02-06-2025
- Business
- Time of India
Bank investments in MFs soar 91% in FY25 amid subdued lending, surplus liquidity
Chalasani of AMFI expects banks' MF investment interest to be strong as the central bank has changed its liquidity stance from neutral to accommodative, leaving scope for sustained surplus liquidity. Banks' mutual fund investments jumped 91% year on year to Rs 1,19,863 crore as on March 21, 2025, from Rs 62,499 crore on March 22, 2024, data from the Reserve Bank of India (RBI) bulletin showed. Banks' MF investments had grown 28% in the previous year. Tired of too many ads? Remove Ads Tired of too many ads? Remove Ads Amid subdued lending and surplus liquidity, banks are earning relatively attractive returns from an untraditional source—mutual funds. Bank s' mutual fund investments jumped 91% year on year to Rs 1,19,863 crore as on March 21, 2025, from Rs 62,499 crore on March 22, 2024, data from the Reserve Bank of India (RBI) bulletin showed. Banks' MF investments had grown 28% in the previous non-SLR (statutory liquidity ratio) investments are remunerative treasury operations that banks engage in with surplus funds in the absence of attractive lending opportunities.'Besides suboptimal credit growth, bank investments in mutual funds schemes have gone up due to surplus liquidity conditions, favourable market conditions and relatively faster execution' explained Vinod A N, general manager and treasury head at South Indian Bank Venkat N Chalasani, CEO of Association of Mutual Funds in India (AMFI) and a former State Bank of India deputy managing director, said, 'Most of these investments are in liquid and money market schemes, which is also reflected in the overall mutual fund investment numbers where investments are in zero risk short-term debt instruments such as treasury bills where returns are comparably higher.'AMFI data for MF assets under management (AUM) in March 2025 shows that over 40 % of the funds are parked in liquid schemes. The returns on such investments can go up as high as 7%, while comparable treasury bill yield is around 5.9%Deploying surplus liquidity in MFs for a short-term period helps banks in asset liability management—to execute a bullish interest rate view and higher yield with the benefit of diversification without sacrificing the quality, exports said.'Unlocking of liquidity is relatively better in the form of MF redemption when compared to direct investments,' Vinod MF investments are expected to remain positive in 2025-26, depending on multiple variables like liquidity, interest rate view, credit growth, etc. 'However, repeating the sharp jump (of FY25) is a tall task,' Vinod said. 'I expect moderate growth in MF investment for the rest of FY26.'Chalasani of AMFI expects banks' MF investment interest to be strong as the central bank has changed its liquidity stance from neutral to accommodative, leaving scope for sustained surplus of the restrictive factors, however, is higher risk weights on these investments for banks which is linked to the quarter end investment positions. Hence, a longer trend of bank investments in MFs show a significant amount of pull-outs during the quarter ending period.
